drugset / Trial / NCT04002661

Hypoactive Sexual Desire Disorder in Males

NCT04002661 ↗

Phase 2 Terminated 8 enrolled Mohit Khera Sprout Pharmaceuticals, Inc · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if the study drug will increase sexual desire in men with HSDD. Half of the participants will take ADDYI while the other half will receive a placebo (a look-alike pill with no medicine).

Timeline

Start
2020-05-08
Primary completion
2025-10-31
Completion
2026-01-23

Outcome

Outcome not reported

Stopped (Enrollment): “The study's inclusion and exclusion criteria are tight and could not enroll any patients”

Drugs

EvaluationDrugModalityDoseRoute
Comparator flibanserin Small molecule 100 mg Oral